Eli Lilly Gets FDA expanded indication for type 2 diabetes treatment Synjardy to add treatment-naïve adults

Eli Lilly and Company

disclosed that the FDA has approved an expanded indication for Synjardy® (empagliflozin and metformin hydrochloride) tablets to include treatment-naïve adults with type 2 diabetes (T2D). According to the company, SYNJARDY, from Boehringer Ingelheim and Eli Lilly, was indicated as an adjunct to diet, as well as, exercise to enhance glycemic control in adults with T2D when treatment with both empagliflozin and metformin is appropriate. Eli Lilly said that SYNJARDY is a combination of both empagliflozin and metformin, i.e. two medicines with complementary mechanisms of action, to support control blood glucose in adults with T2D. The company added that Empagliflozin, a sodium glucose co-transporter-2 inhibitor, take away the excess glucose through the urine by blocking glucose re-absorption in the kidney. The company also indicated that Metformin, which is a commonly prescribed initial treatment for T2D, cuts glucose production by the liver, as well as, its absorption in the intestine. Its president and CEO, Paul Fonteyne, commented, "Type 2 diabetes is a complex condition, which often requires that people take more than one treatment to manage their blood sugar. The expanded indication for SYNJARDY further validates the potential of this combination therapy to help adults with type 2 diabetes who are not at goal, including those already being treated and, now, those at the beginning of their treatment journey." On Monday, the stock closed at $79.95.